Pharvaris

NSQ:PHVS · NL00150005Y4

PharmaceuticalsSmall

360° View

Value9

Price/Sales1

Price/Earnings91

Price/Book5

Dividend Yield1

Growth63

Revenue Growth—

Profit Growth4

Capital Growth90

TSR 52w86

Safety42

Leverage95

Liquidity4

Refinancing35

Combined32

Sentiment75

Analyst Opinions74

Pro Holdings83

Opinion Changes50

Market Pulse37

Profile

CountryNetherlands

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2015

Websitepharvaris.com

ISINNL00150005Y4

Last UpdateApr 2, 2026

Index & Theme

HematologyCentral Nervous SystemGenetic Disorder

Description

Pharvaris N.V. (Pharvaris), a late-stage biopharmaceutical company, focuses on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated…

Analysis

Pharvaris's 360° View rank of 38 places it below its peer average — better than 38% of its true peers.

It's growing solidly (63) and expensive versus peers (9). On safety it is carrying more balance-sheet risk (42), and the market shows favorable sentiment (75). Taken together, its Combined rank of 32 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pharvaris with its peers

Jazz Pharmaceuticals

NSQ:JAZZ

CountryIreland

IndustryPharmaceuticals

SizeLarge

Full Stock Analysis →

ALK-Abelló

CPH:ALK B

CountryDenmark

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Straumann

VTX:STMN

CountrySwitzerland

IndustryHealth Care Equipment & Supplies

SizeLarge

Full Stock Analysis →

Newron Pharmaceuticals

SWX:NWRN

CountryItaly

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

GSK

LSE:GSK

CountryUK

IndustryPharmaceuticals

SizeXX-Large

Full Stock Analysis →

UCB

BRU:UCB

CountryBelgium

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →